NASDAQ:SBFM Sunshine Biopharma (SBFM) Stock Price, News & Analysis $2.76 -0.08 (-2.64%) As of 12:35 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Sunshine Biopharma Stock (NASDAQ:SBFM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sunshine Biopharma alerts:Sign Up Key Stats Today's Range$2.71▼$2.7750-Day Range$2.65▼$23.0052-Week Range$2.53▼$464.00Volume12,774 shsAverage Volume114,841 shsMarket Capitalization$608.30 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingReduce Company Overview Sunshine Biopharma, Inc. is a biotechnology and pharmaceutical company focused on developing and commercializing therapies for cancer and other medical conditions. Its lead oncology candidate, Adva-27a, is an investigational small-molecule drug designed to inhibit topoisomerase II, an enzyme involved in cancer-cell replication. The company has studied the compound in preclinical models, including models of breast cancer and multidrug-resistant tumors. In addition to its drug-development activities, Sunshine Biopharma has expanded into the pharmaceutical products business through its Canadian operations. The company has been associated with the distribution and commercialization of prescription and over-the-counter products in Canada, including generic medicines and other healthcare products. Sunshine Biopharma is headquartered in Canada and has conducted its pharmaceutical and biotechnology activities primarily through its Canadian operations. The company has identified Steve Slilaty as its chief executive officer and has traded on the Nasdaq Capital Market under the symbol SBFM. Its business combines the development of proprietary oncology candidates with pharmaceutical product commercialization.AI Generated. May Contain Errors. Read More Sunshine Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks21st Percentile Overall ScoreSBFM MarketRank™: 1.04821802935 of 5 starsSunshine Biopharma scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingReduce Consensus RatingSunshine Biopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.Amount of Analyst CoverageSunshine Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Sunshine Biopharma's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Sunshine Biopharma are expected to grow in the coming year, from ($39.00) to ($8.00) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sunshine Biopharma is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSunshine Biopharma has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted82.00% of the float of Sunshine Biopharma has been sold short.Short Interest Ratio / Days to CoverSunshine Biopharma has a short interest ratio ("days to cover") of 1.03, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Sunshine Biopharma has recently decreased by 79.03%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSunshine Biopharma does not currently pay a dividend.Dividend GrowthSunshine Biopharma does not have a long track record of dividend growth. News and Social Media1.9 / 5News Sentiment-0.04 News SentimentSunshine Biopharma has a news sentiment score of -0.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Sunshine Biopharma this week, compared to 1 article on an average week.MarketBeat Follows2 people have added Sunshine Biopharma to their MarketBeat watchlist in the last 30 days. Company Ownership0.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sunshine Biopharma insiders have not sold or bought any company stock.Percentage Held by Insiders0.45% of the stock of Sunshine Biopharma is held by insiders.Percentage Held by Institutions41.98% of the stock of Sunshine Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Sunshine Biopharma's insider trading history. Receive SBFM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SBFM Stock News HeadlinesSunshine Biopharma (SBFM) Set to Post Quarterly Earnings on ThursdayNovember 5, 2026 | americanbankingnews.comSunshine Biopharma (SBFM) AI Stock AnalysisNovember 3, 2026 | tipranks.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 13 at 1:00 AM | Paradigm Press (Ad)Sunshine Biopharma consensus price target raised 1,900% to $1,142.40November 1, 2026 | msn.comSunshine Biopharma Prices $6 Million Public Offering; Stock DownOctober 8, 2026 | rttnews.comSunshine Biopharma Prices $6 Million Public Offering at $0.55 Per Unit, Raising Dilution ConcernsOctober 8, 2026 | finance.yahoo.comA Multibillion-Dollar mRNA Cancer Market Is Taking Shape Targeting Lung Cancer’s Biggest OpportunityAugust 26, 2026 | markets.businessinsider.comEXCLUSIVE: Sunshine Biopharma Targets Canadian Market with New Women's Health Drug ApprovalAugust 4, 2026 | benzinga.comSee More Headlines SBFM Stock Analysis - Frequently Asked Questions How have SBFM shares performed this year? Sunshine Biopharma's stock was trading at $246.00 at the beginning of the year. Since then, SBFM stock has decreased by 98.9% and is now trading at $2.74. How were Sunshine Biopharma's earnings last quarter? Sunshine Biopharma, Inc. (NASDAQ:SBFM) posted its earnings results on Thursday, November, 12th. The company reported ($5.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.40) by $1.80. The firm had revenue of $9.44 million for the quarter, compared to analysts' expectations of $9.60 million. Sunshine Biopharma had a negative net margin of 17.94% and a negative trailing twelve-month return on equity of 26.36%. When did Sunshine Biopharma's stock split? Sunshine Biopharma's stock reverse split on Wednesday, April 17th 2024.The 1-100 reverse split was announced on Wednesday, April 17th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 17th 2024. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of Sunshine Biopharma? Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sunshine Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sunshine Biopharma investors own include NVIDIA (NVDA), Tesla (TSLA), ChargePoint (CHPT), Lithium Americas (LAC), NIO (NIO), Broadcom (AVGO) and Clene (CLNN). Company Calendar Last Earnings11/12/2026Today11/13/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (57m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 SBFM's financial health is in the Red zone, according to TradeSmith. SBFM has been in this zone for over 57 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SBFM CIK1402328 Webwww.sunshinebiopharma.com Phone(514) 426-6161FaxN/AEmployees50Year Founded2006Profitability EPS (Trailing Twelve Months)($203.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.97 million Net Margins-17.94% Pretax Margin-15.73% Return on Equity-26.36% Return on Assets-20.60% Debt Debt-to-Equity RatioN/A Current Ratio5.46 Quick Ratio3.30 Sales & Book Value Annual Sales$36.31 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value$938.68 per share Price / Book0.00Miscellaneous Outstanding Shares220,000Free Float215,000Market Cap$608.30 thousand OptionableNot Optionable Beta1.32 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:SBFM) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredA little-known law has been quietly applied to your savings for years.Fox News reported that under current law, legal title to most stocks and bonds sits with a central institution...Monetary Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBFM Stock Alerts